SCHEMBL12758901

SCHEMBL12758901

c1cc(N2CC3(CCC3)C2)cc(C2CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.39
▸ PDE9A O76083 1/20 0.37
▸ PROKR1 Q8TCW9 1/20 0.36
▸ CYP3A4 P08684 7/20 0.35
▸ CYP2C9 P11712 7/20 0.35
▸ CYP2C19 P33261 4/20 0.35
▸ CYP2D6 P10635 3/20 0.35
▸ TSHR P16473 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ HIF1A Q16665 2/20 0.35
▸ TMEM97 Q5BJF2 1/20 0.34
▸ CHRNA7 P36544 1/20 0.33
▸ RIPK1 Q13546 1/20 0.33
▸ USP2 O75604 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ HRH4 Q9H3N8 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12758917 0.84 CYP17A1 (0.38) CYP17A1PROKR1CYP3A4CYP2C9CYP2C19
SCHEMBL19468876 0.79 CYP17A1 (0.46) CYP17A1PROKR1CHRNA7HRH4
SCHEMBL19468823 0.79 HRH4 (0.47) CYP17A1PROKR1ALDH1A1HSD17B10CHRNA7
SCHEMBL12758905 0.76 TMEM97 (0.48) CYP3A4CYP2C9CYP2C19CYP2D6TSHR
SCHEMBL12811492 0.73 EGLN2 (0.48) —
SCHEMBL25506003 0.71 CYP2C9 (0.60) CYP3A4CYP2C9CYP2C19CYP2D6TSHR
SCHEMBL28125294 0.67 HRH4 (0.64) HRH4
SCHEMBL30306686 0.67 LRRK2 (0.47) CYP3A4CYP2C9CYP2C19CYP2D6TSHR
SCHEMBL12758907 0.67 HRH3 (0.41) CYP3A4CYP2C9CYP2C19CYP2D6TSHR
SCHEMBL28177120 0.66 CYP17A1 (0.38) CYP17A1PROKR1CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071129-A1 SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE MSD K.K. (JP) 2011-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071129-A1 SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE MCHR2, MCHR1, ADRB2 CYP17A1 178/4885PDE9A 1834/4885PROKR1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback